Abstract: A method of treating tobacco smoking addiction comprises administering in-vivo to a human body through a tobacco- and smokeless delivery route a product. The product comprises a therapeutic effective amount of a nicotinic agonist, or precursor thereof, in a pharmaceutically acceptable form suitable to release in-vivo in the human body a dose of the nicotinic agonist tolerable by the human body and effective to treat symptoms of a nicotine deficiency in the body induced by the human body being deprived from smoking tobacco. The product further comprises a therapeutic effective amount of a non-psychoactive cannabinoid, or precursor thereof, in a pharmaceutically acceptable form suitable to release in-vivo in the human body a dose of the non-psychoactive cannabinoid tolerable by the human body and effective to treat a craving for smoking tobacco.